surmount 1 tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight – Tirzepatide SURMOUNT-1 three year efficacy

With tirzepatide, the active ingredient in Zepbound, people lost an average of 15% to 21% of their body weight over 72 weeks

The gradual escalation protocol exists to minimize nausea and gastrointestinal side effects while allowing your body to adapt to medication

Conclusion Under real-life conditions, lack of persistence in treatment with GLP-1RA among type 2 diabetes adults with obesity remains a significant concern, particularly since those who were persistent showed improved glycaemic control as compared with non-persistent patients

Specifically, the peptide will interact with MC3R and MC4R

Clinical evidence shows these medications reduce HbA1c (long-term blood sugar marker) by 0.8-1.8%, while patients simultaneously lose 5-15 pounds on average